Prenumeration
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
BioStock today announces the launch of Consensus Analysis, a new editorial format that aggregates and interprets analyst panel views on listed life science companies around quarterly earnings. The inaugural edition focuses on Novo Nordisk.
Published today, on 19 May 2026, the first instalment maps 19 analyst houses covering Novo Nordisk, with share price targets ranging from DKK 175 (Bernstein, Sell) to DKK 440 (SEB, Buy). The format breaks the consensus picture into its constituent parts: recommendation distribution, the catalysts driving panel revisions, and the key signals that investors should monitor going forward.
The launch edition identifies three material observations. Fifteen of the nineteen share price targets pre-date the Novo Nordisk's Q1 report of 6 May, suggesting that consensus has further to travel if the four post-print houses – averaging DKK 329 – are indicative.
Every Buy rating in the panel originates from a Nordic or European house, averaging DKK 372, whilst the seven US houses converge on an average of DKK 247. That translates into a DKK 125 gap that ranks among the widest seen in large-cap European pharma in years. Meanwhile, Novo Nordisk trades at 10.5 times trailing earnings against Eli Lilly's approximately 36 times – the widest relative valuation spread between the two GLP-1 giants in over five years.
The Novo Nordisk Consensus Analysis is available at biostock.se, and equivalent analyses will be published in connection with quarterly earnings seasons for selected companies going forward.